Interestingly, most cancer biomarkers that are routinely detected in blood for diagnosis and prognosis are glycoproteins (e.g., prostate‐specific antigen for the early detection of prostate cancer), the same accounts for biomarkers used to monitor therapy treatment (e.g., carcinoembryonic antigen for various types of cancer) (Hanna‐Sawires et al., 2021; Kirwan et al., 2015). The gene discussed is CEACAM5; the disease is cancer.